Uncategorized
Kala initiates phase 2 trials for RVO, DME treatment
Kala Pharmaceuticals announced the initiation of a phase 2 clinical trial of KP-121, its loteprednol etabonate mucus penetrating particle platform, in patients with retinal vein occlusion and diabetic macular edema.The company is also launching a phase 2 clinical trial of loteprednol etabonate mucus penetrating particle (LE-MPP) in patients with meibomian gland disease, according to a press release.